OSLO, NORWAY and METUCHEN, NJ (June 6, 2017) – NattoPharma has reached an accord with zümXR® that provides NattoPharma with the exclusive rights to add zümXR®’s proprietary, patented encapsulation technology to its Advance Delivery Platform™ (ADP) offering.
ADP enables NattoPharma customers to incorporate MenaQ7® in a broad range of delivery applications, which answers the growing consumer demand for innovative alternative delivery vehicles. This trend is evident in the expanding options for consumers to meet their nutritional needs beyond the traditional dietary supplement, be it with functional food or beverage products, gummies, or other multi-ingredient forms.
A research company that specializes in novel, science-based, targeted-release and encapsulation services based in Denver, CO, USA, zümXR®’s background in the pharmaceutical industry equates to tighter product specifications, stringent quality standards, and an insistence upon delivering products based on science.
“zümXR® complements our existing water soluble and water dispersible delivery systems. All are part of our ADP, which NattoPharma's R&D Solutions Division uses to meet our clients' needs,” says Eric Anderson, NattoPharma senior vice president of global sales and marketing. “Adding this technology to our ADP offering means we can better address an ever-expanding set of customer needs, and assures that we have the right product for our customers’ varied delivery systems.”
“zümXR® is an excellent partner for NattoPharma,” adds Daniel Rosenbaum, NattoPharma CEO. “Like NattoPharma, science drives the innovations zümXR® puts on the market. It is this focus on clinical validation that caught our attention, and having the exclusive right to this proprietary technology adds to our position as a global leader in the Vitamin K2 category.”
About NattoPharma and MenaQ7® NattoPharma ASA,
based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents granted and pending. The company has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPahrma USA, Inc., in Metuchen, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or www.menaq7.com.
Using a patented delivery system, zümXR® develops and sells science-backed targeted-release ingredients and also offers custom encapsulation services. Their patented delivery system gives nutritional supplement and beverage brands the ability to control the release rate and stabilize a variety of ingredients, making current products deliver more usable nutrients and carry stronger label claims. zümXR®’s background in the pharmaceutical industry equates to tighter product specifications and more science behind each product. Current offerings include time-release caffeine versions suitable for both ready-to-drink (RTD) beverages and non-RTD applications (stick pack, gummies, gels). Please visit www.zumxr.com for more information.